214 related articles for article (PubMed ID: 32127023)
21. Stat3 downstream gene product chitinase 3-like 1 is a potential biomarker of inflammation-induced lung cancer in multiple mouse lung tumor models and humans.
Yan C; Ding X; Wu L; Yu M; Qu P; Du H
PLoS One; 2013; 8(4):e61984. PubMed ID: 23613996
[TBL] [Abstract][Full Text] [Related]
22. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein.
Chen Y; Zhang S; Wang Q; Zhang X
J Hematol Oncol; 2017 Feb; 10(1):36. PubMed ID: 28143526
[TBL] [Abstract][Full Text] [Related]
23. A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals.
Lee YS; Yu JE; Kim KC; Lee DH; Son DJ; Lee HP; Jung JK; Kim ND; Ham YW; Yun J; Han SB; Hong JT
Mol Oncol; 2022 Jan; 16(2):508-526. PubMed ID: 34758182
[TBL] [Abstract][Full Text] [Related]
24. Chitinase-3-like-1 deficiency attenuates ethanol-induced liver injury by inhibition of sterol regulatory element binding protein 1-dependent triglyceride synthesis.
Lee DH; Han JH; Lee YS; Jung YS; Roh YS; Yun JS; Han SB; Hong JT
Metabolism; 2019 Jun; 95():46-56. PubMed ID: 30935969
[TBL] [Abstract][Full Text] [Related]
25. HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.
Yang D; Cheng D; Tu Q; Yang H; Sun B; Yan L; Dai H; Luo J; Mao B; Cao Y; Yu X; Jiang H; Zhao X
Theranostics; 2018; 8(13):3517-3529. PubMed ID: 30026863
[TBL] [Abstract][Full Text] [Related]
26. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
Jung KH; Noh JH; Kim JK; Eun JW; Bae HJ; Xie HJ; Chang YG; Kim MG; Park H; Lee JY; Nam SW
J Cell Biochem; 2012 Jun; 113(6):2167-77. PubMed ID: 22492270
[TBL] [Abstract][Full Text] [Related]
27. Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.
Ali A; Bhatti MZ; Shah AS; Duong HQ; Alkreathy HM; Mohammad SF; Khan RA; Ahmad A
J Biol Chem; 2015 Aug; 290(35):21336-51. PubMed ID: 25911104
[TBL] [Abstract][Full Text] [Related]
28. Chitinase 3-like-1, a novel regulator of Th1/CTL responses, as a therapeutic target for increasing anti-tumor immunity.
Kim DH; Choi JM
BMB Rep; 2018 May; 51(5):207-208. PubMed ID: 29699605
[TBL] [Abstract][Full Text] [Related]
29. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model.
Libreros S; Garcia-Areas R; Shibata Y; Carrio R; Torroella-Kouri M; Iragavarapu-Charyulu V
Int J Cancer; 2012 Jul; 131(2):377-86. PubMed ID: 21866546
[TBL] [Abstract][Full Text] [Related]
30. The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.
Van Nostrand JL; Brisac A; Mello SS; Jacobs SB; Luong R; Attardi LD
Cancer Discov; 2015 Jun; 5(6):622-35. PubMed ID: 25813352
[TBL] [Abstract][Full Text] [Related]
31. MICAL2 Mediates p53 Ubiquitin Degradation through Oxidating p53 Methionine 40 and 160 and Promotes Colorectal Cancer Malignance.
Lu J; Li Y; Wu Y; Zhou S; Duan C; Dong Z; Kang T; Tang F
Theranostics; 2018; 8(19):5289-5306. PubMed ID: 30555547
[TBL] [Abstract][Full Text] [Related]
32. FAM188B enhances cell survival via interaction with USP7.
Choi ES; Lee H; Sung JY; Lee CH; Jang H; Kim KT; Kim YN; Kim HP; Goh SH
Cell Death Dis; 2018 May; 9(6):633. PubMed ID: 29795372
[TBL] [Abstract][Full Text] [Related]
33. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
Wang W; Takimoto R; Rastinejad F; El-Deiry WS
Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
[TBL] [Abstract][Full Text] [Related]
34. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
35. Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Li M; Deng Y; Zhuo M; Zhou H; Kong X; Xia X; Su Z; Chen Q; Guo P; Mo P; Yu C; Li W
Theranostics; 2020; 10(19):8863-8879. PubMed ID: 32754284
[No Abstract] [Full Text] [Related]
36. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer.
Wu DW; Liu WS; Wang J; Chen CY; Cheng YW; Lee H
Clin Cancer Res; 2011 Apr; 17(7):1895-905. PubMed ID: 21325288
[TBL] [Abstract][Full Text] [Related]
37. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Valente LJ; Gray DH; Michalak EM; Pinon-Hofbauer J; Egle A; Scott CL; Janic A; Strasser A
Cell Rep; 2013 May; 3(5):1339-45. PubMed ID: 23665218
[TBL] [Abstract][Full Text] [Related]
38. Deletion of Chitinase-3-like 1 accelerates stroke development through enhancement of Neuroinflammation by STAT6-dependent M2 microglial inactivation in Chitinase-3-like 1 knockout mice.
Im JH; Yeo IJ; Park PH; Choi DY; Han SB; Yun J; Hong JT
Exp Neurol; 2020 Jan; 323():113082. PubMed ID: 31669069
[TBL] [Abstract][Full Text] [Related]
39. Decreased Lung Tumor Development in SwAPP Mice through the Downregulation of CHI3L1 and STAT 3 Activity via the Upregulation of miRNA342-3p.
Lee DH; Kim KC; Hwang CJ; Park KR; Jung YS; Kim SY; Kim JY; Song JK; Song MJ; Choi MK; Hwang DY; Han SB; Hong JT
Mol Ther Nucleic Acids; 2019 Jun; 16():63-72. PubMed ID: 30849743
[TBL] [Abstract][Full Text] [Related]
40. DBC1 functions as a tumor suppressor by regulating p53 stability.
Qin B; Minter-Dykhouse K; Yu J; Zhang J; Liu T; Zhang H; Lee S; Kim J; Wang L; Lou Z
Cell Rep; 2015 Mar; 10(8):1324-34. PubMed ID: 25732823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
